Xenetic Biosciences Stock
Xenetic Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James F. Parslow
- Employees
- 2
- Market cap
- $5 M
- IPO
- 30/06/2016
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this…
Xenetic Biosciences stock: price history
1D
-1.0%
1W
-6.6%
1M
-9.1%
6M
-43.6%
YTD
-8.3%
1Y
-54.7%
2Y
-46.4%
5Y
-88.9%
10Y
-99.6%
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~26% weaker price swings than usual
Ask the agents about Xenetic Biosciences
Analyst assessment of Xenetic Biosciences
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 09/04/2025
Xenetic Biosciences stock metrics
P/E
-1.67
P/B
0.75
EV/EBITDA
0.73
RETURN ON EQUITY
-15.3%
NET MARGIN
-140.7%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.3%
FLOAT SHARES
1,975,362
AVG. DAILY VOLUME (30D)
125,210
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Xenetic Biosciences stock
What does Xenetic Biosciences do?
Xenetic Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James F. Parslow, the company employs around 2 people.
The IPO was on 30/06/2016; the stock trades on NASDAQ under the ticker XBIO.
What do analysts say about Xenetic Biosciences stock?
2 analysts rate the stock, the consensus is Buy (as of 09/04/2025).
This is an external assessment, not a statement by Market Jury.
When does Xenetic Biosciences report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
Does Xenetic Biosciences pay a dividend?
No, Xenetic Biosciences currently does not pay a dividend.
Which stocks are comparable to Xenetic Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Xenetic Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Xenetic Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.